GLP-1 supply chain: capacity, constraints, and the 2027 outlook
Executive finding
Fill-finish capacity—not active pharmaceutical ingredient production—is likely to remain the binding constraint through 2026. Announced expansions begin to relieve pressure in late 2026, but execution risk stays concentrated across eleven major sites.sec.govfda.gov
Capacity is arriving in waves
The first meaningful relief comes from brownfield expansions, followed by new U.S. fill-finish lines.
Demand remains the larger uncertainty
Obesity adoption, reimbursement, and oral entrants widen the 2027 scenario range.

